Induction-phase infliximab monitoring accelerates time to remission in pediatric IBD: a retrospective cohort study.

Crohns Colitis 360 · 2026 · PMC13426240 · PMID 42540636

Europe PMC DOI

hedged sentence

0.0060

closest p · 0.1× alpha

0.0060

boldest claim

The sentences

highly significantP = .006actually significant

This relationship remained highly significant when adjusting for starting dose categorically (aHR = 1.717, 95% CI: 1.17, 2.52, P = .006) or continuously (aHR = 1.67, 95% CI: 1.14, 2.43, P = .008).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.